TPX2 and neoplasm: We detected high TPX2 expression in 13.7% of all tumour samples (Fig. 1), which was significantly associated with shorter patient PFS (5.9 vs 2.0 months, P < 0.001, HR 2.74, 95% CI 1.63–4.61, Supplementary Table S5) and OS (9.3 vs 4.4 months, P < 0.001, HR 2.52, 95% CI 1.52–4.16, Supplementary Table S5).